Page 6 - Dr Reddy's
Dr Reddy's Laboratories acquires a portfolio of 42 ANDAs in US
The company said it has entered into a definitive agreement to acquire yet to be marketed portfolio of ANDAs, including more than 30 generic injectable products
 "Dr Reddy's Laboratories acquires a portfolio of 42 ANDAs in US")
Focus on India, emerging markets could drive Dr Reddy's rerating
These markets get a higher valuation compared to the US
Dr Reddy's may take six months to resolve issues flagged by US FDA
Compliance norms to keep Dr Reddy's under pressure
US insurer names Dr Reddy's, dozens of other drug firms in price fixing row
The complaint involves 30 generic drugs, 42 companies; DRL denies wrongdoing, says will vigorously defend itself
Dr Reddy's Q3 net profit up 45% at Rs 485 crore on lower tax outgo
It may be recalled that the company's net profit had declined 29 per cent in the year ago period
Dr Reddy's launches injection for anesthesia and sedation in US market
Dr Reddy's said it uses distribution controls to market Propofol Injectable Emulsion, USP, to prevent any misuse
 "Dr Reddy's launches injection for anesthesia and sedation in US market")
Dr. Reddy's retreats from record after earnings
Dr. Reddy's retreats from record after earnings
Dr Reddy's launches anti-coagulant, dipyridamole drugs in US market
Quoting IMS Health data, Dr Reddy's Laboratories said the Aggrenox brand and generic had US sales of approximately $182 million for the most recent 12 months ending in October 2018
 "Dr Reddy's launches anti-coagulant, dipyridamole drugs in US market")
Dr Reddy's Lab launches heartburn tablet Omeprazole in the US market
Shares of Dr Reddy's were trading 0.20 per cent higher at Rs 2,695 apiece on the BSE
 "Dr Reddy's Lab launches heartburn tablet Omeprazole in the US market")
Dr Reddy's Labs hits 52-week high; stock rallies 5% in two days
The stock hit a 52-week high of Rs 2,700, up 2%, extending its previous day's 3% gain on the BSE, surpassed its previous high of Rs 2,687 recorded on September 28 in intra-day trade.
 "Dr Reddy's Labs hits 52-week high; stock rallies 5% in two days")
Dr Reddy's launches blood pressure drug chlorthalidone tablets in US mar
Chlorthalidone tablets USP in the strengths of 25 mg and 50 mg
Shot in the arm for Dr Reddy's outlook as court clears block on US generic
The stock of Dr Reddy's Laboratories was up about six per cent on the bourses, after an appellate court in the US on Tuesday cleared the way for the company to resume sales of a Suboxone generic. The drug is used to treat opioid addiction and is expected to generate as much as $100 million (a little over Rs 7 billion) in revenue annually.Dr Reddy's had stopped selling the drug after a lower court gave an adverse verdict in June. Prior to the restraining order, the company had reportedly earned $25 mn from the drug, which has an overall market size pegged at $1.8 bn. The development comes as a shot in the arm for Dr Reddy's, which has been struggling to retain its sales growth in the US market, due to fewer big-ticket launches and delayed product approvals. Analysts termed the development a big positive but noted a multiple player market could impact the company's share. Mylan has already settled with Indivior (the innovator) and is expected to soon enter with its own generic version ..
US FDA completes audit of Dr Reddy's Srikakulum plant; stock rises
Shares of Dr.Redyy's closed at Rs 2,470.85 a unit, up by 0.36 per cent compared to the previous close, at BSE on Friday
USFDA's warning letter continues to haunt Dr Reddy's even after 3 years
The latest Form 483 with 8 observations came as a clear setback for the company, which was hoping to complete the remediation without giving a scope for any more observations
 "USFDA's warning letter continues to haunt Dr Reddy's even after 3 years")
Dr Reddy's facility fails to clear the inspections by USFDA yet again
The fresh round of concerns raised by the USFDA inspectors over the Oncology formulations facility comes as a big setback to the company
Dr Reddy's gets USFDA nod to market aspirin, anti-coagulant drug in US
Aspirin is used to treat pain, fever or inflammation while dipyridamole is used as an anti-coagulant
Dr Reddy's Laboratories terminates Armis Biopharma's investigation license
DFA-02 has been studied in several phase 1 and 2 clinical studies
Dr Reddy's gets exclusive right to distribute UCB's epilepsy drug in India
Briviact is approved as an adjunctive therapy for the treatment of partial-onset seizures in epilepsy patients who are 16 years of age and older
US price erosion weighs on Dr Reddy's; Q4 net down 3% to Rs 3 billion
There are not many growth triggers for the company, say analysts
 "US price erosion weighs on Dr Reddy's; Q4 net down 3% to Rs 3 billion")
Dr Reddy's files new drug application for migraine spray with USFDA
Upon approval, the product will be commercialised by Promius Pharma
